According to filings with the U.S. Securities and Exchange Commission, Cellular Longevity dba Loyal is raising up to $32,499,972.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Cellular Longevity dba Loyal
Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives. Weve already achieved significant milestones on our path to gaining FDA approval for the first lifespan extension drug for any species. We have three products in our pipeline and expect to bring the first product to market in 2025. Our team includes scientists, veterinarians, engineers, operators, and creatives. Join us in our mission to help dogs everywhere.

To learn more about Cellular Longevity dba Loyal, visit http://loyal.com/
Cellular Longevity dba Loyal Linkedin Page: https://www.linkedin.com/company/loyalfordogs/

Contact:
Celine Halioua, Chief Executive Officer
408-757-0450
https://www.linkedin.com/in/celinehh/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.